Tuberculosis [TB] is an infectious disease that can affect any part of the body, mainly an infection of the lungs.
In a Neo-Latin word, tuberculosis is termed as ‘TUBERCLE’ which means round nodule and ‘OSIS’ which means condition.
The causative organism for tuberculosis is Mycobacterium tuberculosis in human and Mycobacterium bovis in animals. Mycobacterium tuberculosis is small, aerobic, nonmotile bacillus. The other causative organisms are Mycobacterium africanum and Mycobacterium microti. The non-mycobacterium genuses are Mycobacterium leprae, Mycobacterium avium, Mycobacterium asiaticum. The M.Tuberculosis complex consists of M.africanum, M.bovis, M.canetti, and M.microti.
According to WORLD HEALTH ORGANISATION (WHO), in 2012 they estimated around 8.6 million cases in which women were found approximately around 2.9. Most cases were found in Africa (27%) and Asia (58%), with the highest incidence in India (2.0-2.4 million), China (0.9-1.1 million); and total accounted the number of cases is 38%.
Table of Contents
1. Introduction
2. Epidemiology
3. Pathogenesis
4. Types of tuberculosis
5. Diagnosis
6. Management of tuberculosis
7. Treatment duration and comments
8. Isoniazid drug information
9. Rifampicin drug information
10. Pyrazinamide drug information
11. Ethambutol drug information
12. Streptomycin drug information
Objectives and Topics
This work provides a comprehensive overview of tuberculosis, its epidemiological impact, underlying biological mechanisms, and diagnostic procedures, while focusing on the pharmacological management and the specific profiles of first-line anti-tuberculosis drugs.
- Pathophysiology and transmission dynamics of Mycobacterium tuberculosis
- Global epidemiological trends, mortality, and risk factors like HIV
- Clinical classification and diagnostic methods for pulmonary and extrapulmonary TB
- Pharmacological profiles of first-line anti-TB medications (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Streptomycin)
- Treatment regimens, dosage guidelines, and management of potential adverse effects
Excerpt from the Book
8. Isoniazid
Group – Anti mycobacterial agent
Tablet – 100mg, 300mg
Injection – 25mg/ml in 2ml ampoule
MOA – It is a prodrug and must be activated by the enzyme KatG [23]. This catalyzes the formation of an isonicotinic acyl radical thereby couples with the NADH to form nicotinoyl-NAD. This complex will tightly bind to the carrier protein reductase InhA, thereby blocks the action of fatty acid synthase. This process will inhibit the mycolic acid synthesis. Isoniazid is a monoamine oxidase inhibitor[24].
Pharmacokinetic Data: Isoniazid absorbs rapidly and readily diffuses into all fluids and tissues. The plasma half-life varies from less than one hour in fast acetylators to more than three hours in slow acetylators. It is largely excreted in the urine within 24hrs, mostly as inactive metabolites.
Chapter Summaries
1. Introduction: Defines tuberculosis as an infectious disease primarily affecting the lungs and identifies the causative organisms within the Mycobacterium tuberculosis complex.
2. Epidemiology: Analyzes global TB statistics from 2012, highlighting incidence rates, prevalent cases, mortality figures, and the influence of factors such as HIV and the DOTS strategy.
3. Pathogenesis: Illustrates the biological progression of TB infection from initial exposure to the formation of granulomas and tissue damage.
4. Types of tuberculosis: Distinguishes between pulmonary and various forms of extrapulmonary tuberculosis, including detailed anatomical involvement.
5. Diagnosis: Outlines current diagnostic methodologies, including bacteriological testing, sputum cultures, radiography, and the tuberculin skin test.
6. Management of tuberculosis: Categorizes the essential pharmaceutical interventions into first-line and second-line drugs used for TB therapy.
7. Treatment duration and comments: Presents standard intensive and continuation therapy regimens for managing TB cases.
8. Isoniazid drug information: Details the mechanism of action, pharmacokinetics, dosage, and safety profile of the anti-mycobacterial agent Isoniazid.
9. Rifampicin drug information: Describes the inhibitory effect of Rifampicin on bacterial RNA synthesis and provides relevant clinical data for its administration.
10. Pyrazinamide drug information: Explains the activation of Pyrazinamide as a prodrug and its role in disrupting membrane potential in Mycobacterium tuberculosis.
11. Ethambutol drug information: Covers the mechanism by which Ethambutol obstructs cell wall formation and outlines its clinical usage and side effects.
12. Streptomycin drug information: Explores the use of Streptomycin as an aminoglycoside antibiotic that inhibits protein synthesis in bacteria.
Keywords
Tuberculosis, Mycobacterium tuberculosis, Infectious disease, Pulmonary TB, Extrapulmonary TB, Epidemiology, Diagnosis, DOTS strategy, Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Streptomycin, Chemotherapy, Pharmacology
Frequently Asked Questions
What is the core focus of this publication?
The work focuses on the clinical and pharmacological aspects of tuberculosis, covering everything from the biological basis of the disease to specific treatment protocols.
What are the primary themes addressed?
Key themes include the pathology of TB, global epidemiological trends, diagnostic techniques, and detailed pharmaceutical information regarding standard first-line treatments.
What is the primary goal of the research?
The goal is to provide a structured overview of TB and its advanced therapy, ensuring that medical characteristics and treatment regimens are clearly defined for health management.
Which methods are utilized for diagnosis?
The text describes several diagnostic methods, including bacteriological staining, sputum culture, chest X-rays, nucleic acid amplification, and the tuberculin skin test.
What does the main body of the document cover?
The main body systematically explains the disease progression, its classification, and individual drug profiles for the standard four-drug regimen.
How is the work characterized in terms of terminology?
The work is characterized by technical medical keywords related to microbiology, pharmacology, and clinical pathology of infectious diseases.
What is the mechanism of action for Isoniazid?
Isoniazid acts as a prodrug activated by the enzyme KatG, which then inhibits mycolic acid synthesis by binding to the carrier protein reductase InhA.
How does Rifampicin interact with other drugs?
Rifampicin induces hepatic enzymes, which can increase the dosage requirements for various drugs such as anticoagulants, phenytoin, and hormonal contraceptives.
Why is Pyrazinamide considered a prodrug?
It requires conversion by the enzyme pyrazinamidase into its active form, pyrazinoic acid, to inhibit the growth of the bacteria.
What specific precautions are required for Streptomycin usage?
Patients receiving Streptomycin must be monitored to avoid ototoxicity and nephrotoxicity, and the drug should not be administered alongside other nephrotoxic or ototoxic agents.
- Quote paper
- Dr. Sagar Pamu (Author), 2018, Tuberculosis and its Advanced Therapy, Munich, GRIN Verlag, https://www.hausarbeiten.de/document/423950
